CAR-T细胞治疗中免疫监测的前景：EBMT细胞治疗和免疫生物学工作组的全面回顾和调查研究。

IF 6.9 2区医学 Q1 HEMATOLOGY

Blood Reviews Pub Date : 2025-02-15 DOI:10.1016/j.blre.2025.101272

Simona Pagliuca , Florent Malard , Jarl E. Mooyaart , Michael Daskalakis , Ludovic Gabellier , Ibrahim Yakoub-Agha , Ron Ram , Caroline Besley , Edouard Forcade , Vladan Vucinic , Lucía López Corral , Jan Vydra , Bastian von Tresckow , Paula Amat , Persis Amrolia , Peter Vandenberghe , Friedrich Stölzel , Simona Sica , Marie Thérèse Rubio , Jorinde D. Hoogenboom , Annalisa Ruggeri

{"title":"CAR-T细胞治疗中免疫监测的前景：EBMT细胞治疗和免疫生物学工作组的全面回顾和调查研究。","authors":"Simona Pagliuca , Florent Malard , Jarl E. Mooyaart , Michael Daskalakis , Ludovic Gabellier , Ibrahim Yakoub-Agha , Ron Ram , Caroline Besley , Edouard Forcade , Vladan Vucinic , Lucía López Corral , Jan Vydra , Bastian von Tresckow , Paula Amat , Persis Amrolia , Peter Vandenberghe , Friedrich Stölzel , Simona Sica , Marie Thérèse Rubio , Jorinde D. Hoogenboom , Annalisa Ruggeri","doi":"10.1016/j.blre.2025.101272","DOIUrl":null,"url":null,"abstract":"<div><div>Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"71 ","pages":"Article 101272"},"PeriodicalIF":6.9000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT\",\"authors\":\"Simona Pagliuca , Florent Malard , Jarl E. Mooyaart , Michael Daskalakis , Ludovic Gabellier , Ibrahim Yakoub-Agha , Ron Ram , Caroline Besley , Edouard Forcade , Vladan Vucinic , Lucía López Corral , Jan Vydra , Bastian von Tresckow , Paula Amat , Persis Amrolia , Peter Vandenberghe , Friedrich Stölzel , Simona Sica , Marie Thérèse Rubio , Jorinde D. Hoogenboom , Annalisa Ruggeri\",\"doi\":\"10.1016/j.blre.2025.101272\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.</div></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":\"71 \",\"pages\":\"Article 101272\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X25000177\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X25000177","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

细胞治疗的免疫监测是一个复杂而不断发展的话题，特别是在嵌合抗原受体T （CAR-T）细胞应用的快速扩展领域。定义car -t细胞输注后的基本、推荐和可选免疫监测数据对于改善患者预后和告知治疗后决策至关重要。为了解决这一差距，我们在欧洲血液和骨髓移植协会（EBMT）附属中心进行了一项基于调查的研究，重点关注使用欧洲药品管理局（EMA）批准的CAR-T产品治疗的患者。在对文献进行全面回顾的基础上，我们绘制了免疫监测实践的当前图景，并评估了它们对临床管理的影响。通过定义该领域的最新技术，这项工作标志着朝着结构化协调过程迈出了第一步，这一过程有可能增强接受这些免疫细胞疗法的患者的管理和结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT

Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.